Monte Rosa Therapeutic (GLUE) Barclays 28th Annual Global Healthcare Conference summary

Platform technology and scientific differentiation

• Molecular glue degraders enable targeting of previously undruggable proteins by reshaping E3 ligase surfaces, facilitating protein-protein interactions for degradation without requiring a binding site.

• Compared to heterobifunctional degraders, molecular glues offer a broader pharmacodynamic index and catalytic mechanism, allowing one molecule to degrade thousands of target proteins.

Pipeline highlights and clinical progress

• MRT-6160 (VAV1 degrader) is licensed to Novartis, with multiple phase II trials in autoimmunity planned for 2024.

• MRT-8102 (NEK7 degrader) is in clinical development, with early data showing significant CRP reduction and favorable safety.

• GFORCE-1 study tests MRT-8102 in high cardiovascular risk subjects, with expanded dose cohorts and data update expected in H2 2024.

• GFORCE-2 phase II study for MRT-8102 will start in H2 2024, focusing on longer administration and safety before phase III readiness.

Mechanistic insights and clinical data

• NEK7 degradation blocks NLRP3 inflammasome assembly, providing sustained pharmacodynamic effects and differentiating from direct NLRP3 inhibitors.

• Phase I data for MRT-8102 showed up to 85% CRP reduction at week four, with no significant adverse events across a wide dose range.

• GFORCE-1 design includes multiple dose levels and placebo in obese subjects with elevated CRP, aiming to optimize dose-response understanding.